Serum procalcitonin and CRP levels in non-alcoholic fatty liver disease: a case control study

Farrell GC: Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?. J Gastroenterol Hepatol. 2003, 18: 124-138. 10.1046/j.1440-1746.2003.02989.x.

Angulo P: Nonalcoholic fatty liver disease. N Engl J Med. 2002, 18: 1221-1231. 10.1056/NEJMra011775.

Chitturi S, Abeygunasakera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J: NASH and insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002, 35: 373-379. 10.1053/jhep.2002.30692.

Björnsson E: The clinical aspects of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol. 2008, 54 (1): 7-18.

Massaro KS, Costa SF, Leone C, Chamone DA: Procalcitonin (PCT) and C-reactive protein (CRP) as severe systemic infection markers in febrile neutropenic adults. BMC Infect Dis. 2007, 22: 137-10.1186/1471-2334-7-137.

Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW: C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol. 1999, 19: 972-978.

Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB: Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000, 321: 199-204. 10.1136/bmj.321.7255.199.

Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000, 342: 836-843. 10.1056/NEJM200003233421202.

Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J: Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004, 39: 206-217. 10.1086/421997.

Maruna P, Nedelnikova K, Gurlich R: Physiology and genetics of procalcitonin. Physiol Res. 2000, 49 Suppl 1: S57-S61.

Matthews DR, Hoskër JP, Rudenski AS, Naylor BA, Treacher DF, Tumer RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985, 28: 412-419. 10.1007/BF00280883.

Connert S, Stremmel W, Elsing C: Procalcitonin is a valid marker of infection in decompensated cirrhosis. Z Gastroenterol. 2003, 41: 165-170. 10.1055/s-2003-37314.

Viallon A, Zeni F, Pouzet V, Lambert C, Quenet S, Aubert G, Guyomarch S, Tardy B, Bertrand JC: Serum and ascitic procalcitonin levels in cirrhotic patients with spontaneous bacterial peritonitis: diagnostic value and relationship to pro-inflammatory cytokines. Intensive Care Med. 2000, 26: 1082-1088. 10.1007/s001340051321.

Elefsiniotis IS, Skounakis M, Vezali E, Pantazis KD, Petrocheilou A, Pirounaki M, Papatsibas G, Kontou-Kastellanou C, Moulakakis A: Clinical significance of serum procalcitonin levels in patients with acute or chronic liver disease. Eur J Gastroenterol Hepatol. 2006, 18: 525-530. 10.1097/00042737-200605000-00012.

Spahr L, Morard I, Hadengue A, Vadas L, Pugin J: Procalcitonin is not an accurate marker of spontaneous bacterial peritonitis in patients with cirrhosis. Hepatogastroenterology. 2001, 48: 502-505.

Haukeland JW, Damås JK, Konopski Z, Løberg EM, Haaland T, Goverud I, Torjesen PA, Birkeland K, Bjøro K, Aukrust P: Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol. 2006, 44: 1167-1174. 10.1016/j.jhep.2006.02.011.

Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, Kato S, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Abe Y, Kubota K, Saito S, Iwasaki T, Terauchi Y, Togo S, Maeyama S, Nakajima A: High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol. 2007, 42: 573-582. 10.1007/s00535-007-2060-x.

Riquelme A, Arrese M, Soza A, Morales A, Baudrand R, Pérez-Ayuso RM, González R, Alvarez M, Hernández V, García-Zattera MJ, Otarola F, Medina B, Rigotti A, Miquel JF, Marshall G, Nervi F: Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int. 2009, 29: 82-88. 10.1111/j.1478-3231.2008.01925.x.

Kao PC, Shiesh SC, Wu TJ: Serum C-reactive protein as a marker for wellness assessment. Ann Clin Lab Sci. 2006, 36: 163-169.

Anty R, Bekri S, Luciani N, Saint-Paul MC, Dahman M, Iannelli A, Amor IB, Staccini-Myx A, Huet PM, Gugenheim J, Sadoul JL, Le Marchand-Brustel Y, Tran A, Gual P: The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, Type 2 diabetes, and NASH. Am J Gastroenterol. 2006, 101: 1824-1833. 10.1111/j.1572-0241.2006.00724.x.

Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, Bohuon C: Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab. 1994, 79: 1605-1608. 10.1210/jc.79.6.1605.